Literature DB >> 23670667

Longitudinal trends in health-related quality of life in adults with cystic fibrosis.

Edward J Dill1, Ree Dawson2, Deborah E Sellers3, Walter M Robinson3, Gregory S Sawicki4.   

Abstract

BACKGROUND: Health-related quality-of-life (HRQOL) measures have been used as patient-reported outcomes in clinical trials in cystic fibrosis (CF), but there are limited data on HRQOL changes over time in adults with CF.
METHODS: The Project on Adult Care in Cystic Fibrosis, a prospective, longitudinal panel study of 333 adults with CF at 10 CF centers in the United States, administered a disease-specific HRQOL measure, the Cystic Fibrosis Questionnaire-Revised (CFQ-R), seven times over 21 months. The CFQ-R assesses both physical and psychosocial domains of health. Growth curve regression models were developed for each CFQ-R domain, adjusting for demographic and clinical characteristics.
RESULTS: Between 205 and 303 adults completed surveys (response rate, 70%-93%). Mean age at baseline was 33 years (range, 19-64 years); mean FEV1 % predicted was 59.8% (SD, 22%). Over the 21 months of follow-up, lung function, frequency of pulmonary exacerbations, and nutritional indices were associated with physical CFQ-R domain scores. There were no significant population trends over time in the physical domain scores; however, there were population time trends in three psychosocial domains: treatment burden (+8.9 points/y), emotional functioning (+3.2 points/y), and social functioning (-2.4 points/y). Individual variation in both physical and psychosocial subscales was seen over 21 months.
CONCLUSIONS: In a longitudinal multicenter population of adults with CF, clinical variables such as FEV1, exacerbation frequency, and weight were correlated with related CFQ-R subscales. For the population as a whole, the physical domains of CFQ-R, such as respiratory symptoms, were stable. In contrast, population changes in several psychosocial domains of CFQ-R suggest that differentiating between the physical and the psychosocial trajectories in health among adults with CF is critical in evaluating patient-reported outcomes.

Entities:  

Mesh:

Year:  2013        PMID: 23670667      PMCID: PMC3760745          DOI: 10.1378/chest.12-1404

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  25 in total

1.  Self-reported physical and psychological symptom burden in adults with cystic fibrosis.

Authors:  Gregory S Sawicki; Deborah E Sellers; Walter M Robinson
Journal:  J Pain Symptom Manage       Date:  2008-01-22       Impact factor: 3.612

2.  Monitoring quality of life in outpatients with cystic fibrosis: feasibility and longitudinal results.

Authors:  Lutz Goldbeck; Sven Zerrer; Tim G Schmitz
Journal:  J Cyst Fibros       Date:  2006-07-31       Impact factor: 5.482

3.  Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

Authors:  Patrick A Flume; Brian P O'Sullivan; Karen A Robinson; Christopher H Goss; Peter J Mogayzel; Donna Beth Willey-Courand; Janet Bujan; Jonathan Finder; Mary Lester; Lynne Quittell; Randall Rosenblatt; Robert L Vender; Leslie Hazle; Kathy Sabadosa; Bruce Marshall
Journal:  Am J Respir Crit Care Med       Date:  2007-08-29       Impact factor: 21.405

4.  High treatment burden in adults with cystic fibrosis: challenges to disease self-management.

Authors:  Gregory S Sawicki; Deborah E Sellers; Walter M Robinson
Journal:  J Cyst Fibros       Date:  2008-10-26       Impact factor: 5.482

Review 5.  Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.

Authors:  Alexandra L Quittner; Avani C Modi; Claire Wainwright; Kelly Otto; Jean Kirihara; A Bruce Montgomery
Journal:  Chest       Date:  2009-05-15       Impact factor: 9.410

6.  Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.

Authors:  George Z Retsch-Bogart; Alexandra L Quittner; Ronald L Gibson; Christopher M Oermann; Karen S McCoy; A Bruce Montgomery; Peter J Cooper
Journal:  Chest       Date:  2009-05       Impact factor: 9.410

Review 7.  Patient-reported outcomes in cystic fibrosis.

Authors:  Christopher H Goss; Alexandra L Quittner
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

8.  Can health-related quality of life predict survival in adults with cystic fibrosis?

Authors:  Janice Abbott; Anna Hart; Alison M Morton; Paola Dey; Steven P Conway; A Kevin Webb
Journal:  Am J Respir Crit Care Med       Date:  2008-10-23       Impact factor: 21.405

9.  Health-related quality of life in adults with cystic fibrosis: the role of coping.

Authors:  Janice Abbott; Anna Hart; Alison Morton; Louise Gee; Steven Conway
Journal:  J Psychosom Res       Date:  2008-02       Impact factor: 3.006

10.  Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.

Authors:  Karen S McCoy; Alexandra L Quittner; Christopher M Oermann; Ronald L Gibson; George Z Retsch-Bogart; A Bruce Montgomery
Journal:  Am J Respir Crit Care Med       Date:  2008-07-24       Impact factor: 21.405

View more
  20 in total

1.  The presence of Aspergillus fumigatus is associated with worse respiratory quality of life in cystic fibrosis.

Authors:  Gina Hong; Kevin Alby; Sharon C W Ng; Victoria Fleck; Christina Kubrak; Ronald C Rubenstein; Daniel J Dorgan; Steven M Kawut; Denis Hadjiliadis
Journal:  J Cyst Fibros       Date:  2019-08-21       Impact factor: 5.482

2.  Use of a Multiplex Transcript Method for Analysis of Pseudomonas aeruginosa Gene Expression Profiles in the Cystic Fibrosis Lung.

Authors:  Alex H Gifford; Sven D Willger; Emily L Dolben; Lisa A Moulton; Dana B Dorman; Heather Bean; Jane E Hill; Thomas H Hampton; Alix Ashare; Deborah A Hogan
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

3.  Genetic Variation Near chrXq22-q23 Is Linked to Emotional Functioning in Cystic Fibrosis.

Authors:  Eric Barbato; Barbara Daly; Sara Douglas; Mary Kerr; Paul Litman; Rebecca Darrah
Journal:  Biol Res Nurs       Date:  2020-05-11       Impact factor: 2.522

4.  Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.

Authors:  Don B Sanders; Qianqian Zhao; Zhanhai Li; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2017-09-07

5.  Reciprocal Links Between Physical Health and Coping Among Adolescents With Cystic Fibrosis.

Authors:  Christina M D'Angelo; Sylvie Mrug; Daniel Grossoehme; Kevin Leon; Lacrecia Thomas; Bradley Troxler
Journal:  J Pediatr Psychol       Date:  2021-02-19

6.  Healthcare system supports for young adult patients with pediatric onset chronic conditions: a qualitative study.

Authors:  Dava E Szalda; Manuel E Jimenez; Jeremiah E Long; Amelia Ni; Judy A Shea; Sophia Jan
Journal:  J Pediatr Nurs       Date:  2014-10-13       Impact factor: 2.145

7.  Longitudinal impact of demographic and clinical variables on health-related quality of life in cystic fibrosis.

Authors:  Janice Abbott; Alison M Morton; Margaret A Hurley; Steven P Conway
Journal:  BMJ Open       Date:  2015-05-19       Impact factor: 2.692

8.  Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.

Authors:  Srilekha Panguluri; Praveen Gunda; Laurie Debonnett; Kamal Hamed
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

9.  Factors associated with changes in health-related quality of life in children with cystic fibrosis during 1-year follow-up.

Authors:  Marieke van Horck; Bjorn Winkens; Geertjan Wesseling; Karin de Winter-de Groot; Ilja de Vreede; Quirijn Jöbsis; Edward Dompeling
Journal:  Eur J Pediatr       Date:  2017-06-09       Impact factor: 3.183

Review 10.  Measuring the burden of treatment for chronic disease: implications of a scoping review of the literature.

Authors:  Adem Sav; Asiyeh Salehi; Frances S Mair; Sara S McMillan
Journal:  BMC Med Res Methodol       Date:  2017-09-12       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.